Articles

Benefits of semaglutide for weight loss

by Total Compounding Pharmaceuticals Total Compounding Pharmaceuticals
Semaglutide is a drug that is used to treat type 2 diabetes and obesity. It belongs to the class of medicines known as glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists). There are following semaglutide health benefits are-

1. Better glycemic control: Semaglutide improves blood sugar control by boosting insulin secretion, lowering glucagon synthesis, and slowing gastric emptying. This may result in better blood glucose control in persons with type 2 diabetes.

2. Weight loss: Semaglutide has been demonstrated to stimulate weight loss, making it useful for people with type 2 diabetes who are obese or overweight. It was especially licensed for weight control in persons with a BMI of 27 kg/m2 or more, as well as those with obesity-related diseases, at a larger dose (2.4 mg) under the trade name Wegovy.

3. Cardiovascular benefits: Clinical investigations have shown that semaglutide offers cardiovascular advantages. It has been found to lower the risk of significant adverse cardiovascular events, such as heart attack and stroke, among persons with type 2 diabetes who are predisposed to them.

4. Blood pressure control: Semaglutide can help lower blood pressure levels in people with type 2 diabetes, lowering the risk of hypertension-related problems.

5. Potential advantages for non-alcoholic fatty liver disease (NAFLD): Some research suggests that semaglutide may be beneficial for non-alcoholic fatty liver disease (NAFLD), a disorder characterized by fat accumulation in the liver.

It is crucial to remember that semaglutide, like any medicine, may cause negative effects and should only be used as directed by a doctor.

Sponsor Ads


About Total Compounding Pharmaceuticals Advanced   Total Compounding Pharmaceuticals

20 connections, 0 recommendations, 118 honor points.
Joined APSense since, December 5th, 2023, From Sheridan, United States.

Created on Dec 14th 2023 06:48. Viewed 117 times.

Comments

No comment, be the first to comment.
Please sign in before you comment.